These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 7594705)
21. Human immunodeficiency virus type 1 phenotypes in children with advanced disease treated with long-term zalcitabine. Viani RM; Smith IL; Spector SA J Infect Dis; 1998 Mar; 177(3):565-70. PubMed ID: 9498433 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of 2',3'-dideoxycytidine after high-dose administration to rats. Ibrahim SS; Boudinot FD J Pharm Sci; 1991 Jan; 80(1):36-8. PubMed ID: 1849573 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. Klecker RW; Collins JM; Yarchoan RC; Thomas R; McAtee N; Broder S; Myers CE J Clin Pharmacol; 1988 Sep; 28(9):837-42. PubMed ID: 2852679 [TBL] [Abstract][Full Text] [Related]
26. Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. Uckun FM; Bellomy K; O'Neill K; Messinger Y; Johnson T; Chen CL J Pharmacol Exp Ther; 1999 Dec; 291(3):1301-7. PubMed ID: 10565855 [TBL] [Abstract][Full Text] [Related]
27. Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients. Herzmann C; Arastèh K; Murphy RL; Schulbin H; Kreckel P; Drauz D; Schinazi RF; Beard A; Cartee L; Otto MJ Antimicrob Agents Chemother; 2005 Jul; 49(7):2828-33. PubMed ID: 15980356 [TBL] [Abstract][Full Text] [Related]
28. Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Hurwitz SJ; Otto MJ; Schinazi RF Antivir Chem Chemother; 2005; 16(2):117-27. PubMed ID: 15889534 [TBL] [Abstract][Full Text] [Related]
29. Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center. Pediatr Infect Dis J; 1993 Jun; 12(6):513-22. PubMed ID: 8393969 [No Abstract] [Full Text] [Related]
30. Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease. Matthews SJ; Cersosimo RJ; Spivack ML Pharmacotherapy; 1991; 11(6):419-48; discussion 448-9. PubMed ID: 1722897 [TBL] [Abstract][Full Text] [Related]
31. Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration? Aweeka FT; Brody SR; Jacobson M; Botwin K; Martin-Munley S Clin Ther; 1998; 20(2):232-43. PubMed ID: 9589815 [TBL] [Abstract][Full Text] [Related]
32. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS. AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371 [TBL] [Abstract][Full Text] [Related]
33. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399 [TBL] [Abstract][Full Text] [Related]
34. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838 [TBL] [Abstract][Full Text] [Related]
35. A kinder, gentler ddC... for $7,200 a year. GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362996 [TBL] [Abstract][Full Text] [Related]
36. [Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus]. Soriano Vázquez V; Rodríguez-Rosado Martínez-Echevarría R; Jiménez-Nacher I; Valencia Ortega E; Moreno Celda V; González-Lahoz J Rev Clin Esp; 1998 Sep; 198(9):634-5. PubMed ID: 9803794 [No Abstract] [Full Text] [Related]
37. Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis. Borg N; Ståhle L Antimicrob Agents Chemother; 1998 Sep; 42(9):2174-7. PubMed ID: 9736530 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness. Simon MW; Fish DN; Deeter RG Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939 [TBL] [Abstract][Full Text] [Related]
39. Treatment options for human immunodeficiency virus. Heins JR S D J Med; 1996 Feb; 49(2):51-2. PubMed ID: 9122670 [No Abstract] [Full Text] [Related]